Kornimate/medical-research-clean huggingface dataset:
impact of interferon free regimens in patients with chronic hcv and successfully treated hcc

Conditions: Hepatitis C, Chronic; Hepatocellular Carcinoma

Summary: the study will recruit 150 patients with hcv related hcc ,after hcc treatment the patients will undergo treatment with different regimens of daas.

the study will recruit 150 patients with hcv related hcc all the studied patients underwent or will undergo one of the curative interventions for hcc either hepatic resection or thermal ablation . after 1 month of achievement of laboratory and radiological response to hcc intervention the patient will be treated with one of the interferon free regimens : 1. sofosbuvir+ribavirin 2. sofosbuvir+simeprevir± ribavirin 3. sofosbuvir+ daclatasvir ± ribavirin 4. sofosbuvir+ ledipasvir ± ribavirin the treatment duration will be justified either 12 or 24 weeks after treatment the patient will continue on regular follow up to detect hcv cure or recurrence , hcc cure or recurrence and long term follow up of natural history

Eligibility criteria:
inclusion criteria: * age 18-70 years old * confirmed hcv viremia by pcr * child pugh "a" or "b7,b8" * confirmed hcc either by laboratory ,imaging or histopathological criteria * underwent or candidate for curative intervention for hcc (bclc stage 0 ,a) * willing to be treated for hcv and signing informed consent exclusion criteria: * patients below 18 or above 70 years old * patients with advanced liver condition "child score ≥ b9" * patients with advanced hcc status (bclc≥ b) * patients with combined hbv ,hiv infection

Keywords: hcv-hcc-daas
clinical study of translocated internal limiting membrane flap reposition for the treatment of idiopathic macular hole

Conditions: Macular Holes

Summary: the main objective of this study is to evaluate the therapeutic effectiveness of the internal limiting membrane (ilm) peeling and translocation surgery compared to the conventional surgical approach for treating large idiopathic macular hole (imh) through a well-designed prospective randomized controlled clinical trial. this study aims to compare the new surgical approach to the conventional approach in terms of improving visual function, promoting macular retinal anatomical healing, and enhancing patients' quality of life. by conducting this prospective clinical trial, establishing a database, and generating clinical reports and evidence-based medicine on the therapeutic efficacy of the ilm peeling and translocation surgery for large imh.


Eligibility criteria:
inclusion criteria: * participants who can understand the purpose of this clinical trial, volunteer to participate, sign an informed consent form, and can complete the postoperative follow-up on time. * participants diagnosed with idiopathic macular hole (imh). * based on oct scans, the minimum horizontal diameter of the macular hole is \>500 and \<900 µm. * participants with an axial length \<26.0mm and a myopic degree lower than 6d. * for participants with bilateral macular holes, the eye with a larger hole diameter will be included. exclusion criteria: * patients with the following retinal disorders: age-related macular degeneration, epi-macular membrane neovascularization, non-macular retinal tears, lesions of the retinal pigment epithelium and choroid, inherited or degenerative retinal diseases, optic neuropathies, retinal vascular diseases; patients with large macular holes accompanied by retinal detachment; * patients with high myopia (axial length ≥ 26.0mm and myopia exceeding 6d); * patients with a history of ocular trauma or retinal laser treatment; * patients with glaucoma, ocular infections, inflammations, tumors, corneal diseases, or amblyopia; * patients with contraindications to vitrectomy; * patients with severe or unstable systemic diseases; * patients with a fasting blood glucose level ≥ 9mmol/l before surgery; * patients who participated in other clinical trials involving drugs or medical devices within 30 days prior to screening; * patients with a history of intraocular surgery within 3 months prior to screening; * patients with reduced visual function or vision in the contralateral eye as determined by the investigator; * patients who are not considered suitable for enrollment by the investigator for other reasons.
nimotuzumab combined with radiotherapy for older patients with esophageal cancer: a single, non-control clinical trial

Conditions: Esophageal Cancer

Summary: for patients who are unable to receive surgery or having local advanced esophageal cancer stages, concurrent chemoradiotherapy is recommended. but radiotherapy is the main strategy for older patients because of their chemoradiotherapy intolerance. the whole world focused on targeted therapy which has strong specialties and mild toxicities. so combined targeted therapy and radiotherapy may be a novel strategy for older patients with esophageal cancer. nimotuzumab is a egfr monoclonal antibody. this clinical trial is to study the effect and safety of nimotuzumab in combined with radiotherapy for older patients with esophageal cancer. all patients receive intensity modulated radiotherapy with conventional fraction. nimotuzumab with 200mg is given weekly for all patients during radiotherapy.

study design primary purpose: to evaluate the response rate, progression-free survival, overall survival and complications. study phase: phase ii intervention model: targeted therapy combined with radiotherapy number of arms: one masking: no allocation: 30 patients for one single group enrollment: 30 patients eligibility criteria inclusion criteria: 1. ≥ 70 year-old, 2. thoracic segment esophageal cancer with stage ii to iv (supraclavicular lymph node metastasis only), 3. no previous surgery, radiotherapy or chemotherapy of cancer was allowed, 4. estimated survival time ≥ 3 months, 5. kps \> 60, 6. no serious diseases of important organs, 7. signed consent forms voluntarily. exclusion criteria: 1. psychopath, 2. history of other malignant disease which has not been cured, 3. joining other clinical trial prior this study.

Eligibility criteria:
inclusion criteria: 1. patients aged 70 years or older; 2. treatment naive patients with histologically proven thoracic-segment ec that was inoperable and who could not tolerate ccrt; 3. stage ii-iv disease (supraclavicular lymph node metastasis only), according to the 6th american joint committee on cancer tnm staging system; 4. estimated survival time ≥3 months; 5. karnofsky performance score ≥70; 6. adequate bone marrow, as well as hepatic and renal function; 7. voluntary written consent provided prior to treatment. exclusion criteria: 1. esophagobronchial or esophagomediastinal fistula; 2. patients who had joined other clinical trials prior to this treatment; 3. serious heart, liver, and/or kidney insufficiency; 4. serious infectious disease; 5. relapse disease or distant metastasis; 6. recently diagnosed neoplastic diseases; 7. previous receipt of surgery, chemotherapy, or radiotherapy for ec.

Keywords: radiotherapy targeted therapy esophageal cancer older
tmao in patients with severe aortic stenosis

Conditions: Aortic Stenosis; Heart Failure

Summary: trimethylamine n-oxide (tmao) has recently gained increasing scientific interest in the field of cardiovascular disease, including its role in cell protection against osmotic and hydrostatic stress. aortic stenosis (as) is the most common valvular heart disease, affecting about 7.6 million people over 75 years of age in north america and europe alone. we hypothesized that tmao plays a role in protection of the cardiomyocytes against pressure overload in patients with as. the primary aim of this study is to assess the correlation between the serum and urine tmao concentration, and (i) echocardiographic, (ii) biochemical and (iii) histopathological parameters of heart failure in patients with severe as. the secondary aim of this study is to evaluate a correlation between the baseline tmao concentrations and the post-treatment clinical status, as well as the post-treatment echocardiographic and biochemical parameters.


Eligibility criteria:
inclusion criteria: * informed consent to participate in the study * severe aortic stenosis, defined as aortic valve area \<1.0 cm2 or aortic valve area index \<0.6 cm2/m2 as calculated by the continuity equation on transthoracic echocardiography, regardless of the transvalvular gradient, with or without coexisting symptoms of heart failure * qualification for surgical aortic valve replacement or transcatheter aortic valve implantation by the heart team in accordance with european society of cardiology guidelines exclusion criteria: * heart failure of etiology other than aortic stenosis * coexisting, haemodynamically significant aortic regurgitation * myocardial infarction within the last 3 months * coronary revascularization within the last month or planned during transcatheter aortic valve implantation or surgical aortic valve replacement * chronic kidney disease with estimated glomerular filtration rate \<45 ml/min/1.73 m2 * acute gastrointestinal disease within the last month * active neoplastic disease * chronic inflammatory disease * autoimmune disease * chronic intestinal disease * antibiotic therapy within the last 2 months * dietary supplements within the last 7 days

Keywords: aortic stenosis heart failure trimethylamine tmao bacterial metabolites
evaluation of the efficacy and safety of silodosin in the treatment of the signs and symptoms of bph

Conditions: Benign Prostatic Hyperplasia

Summary: a new drug for the treatment of benign prostatic hyperplasia is compared with placebo and tamsulosin (a drug belonging to the same therapeutic class) for to determine if it is safe and effective (the first phase of the study lasts approximately 18 weeks) and then is used for another 9 months to determine its long-term safety.

this is a multi-centre, double-blind, placebo and active controlled, parallel 12 week treatment trial in men with signs and symptoms of benign prostatic hyperplasia, followed by a 9 month open-label phase. the following procedures are used: physical exams, electrocardiograms, clinical laboratory tests, vital signs, the international prostate symptom score, maximum urine flow rate, adverse events, concomitant medications, quality of life and compliance. 93 centres in 11 european countries (finland, france, germany, italy, netherlands, poland, romania, russia, spain, ukraine, uk) will be involved

Eligibility criteria:
inclusion criteria: * males in good general health and at least 50 years of age, with symptoms of moderate to severe benign prostatic hyperplasia exclusion criteria: * medical conditions that would confound the efficacy evaluation * medical conditions in which it would be unsafe to use an alpha-blocker * use of concomitant drugs that would confound the efficacy evaluation * use of concomitant drugs that would be unsafe with this alpha-blocker

Keywords: benign prostatic hyperplasia alpha-blockers
results of ocular compression and suture release in trabeculectomy and combined surgery

Conditions: Primary Open Angle Glaucoma

Summary: the use of ocular compression and suture release have helped to improve the safety and decrease the risks of glaucoma filtering surgery. this study looks at the decrease in intraocular pressure and glaucoma medications required following glaucoma filtering surgery.

a retrospective review of surgical results in eyes with at least six months followup was performed for trabeculectomy and combined phacoemulsification-trabeculectomy surgery. a total of 141 eyes were studied.

Eligibility criteria:
inclusion criteria: * primary open angle glaucoma * six months followup * no previous surgery exclusion criteria: * less than six months followup * previous glaucoma surgery

Keywords: poag primary open angle glaucoma trabeculectomy combined phacotrabeculectomy combined glaucoma cataract surgery releasable suture ocular compresssion
pilot study of a nerve block simulator for the training in axillary blocks

Conditions: Arm Injuries

Summary: the purpose of this study is to determine whether an ultrasound-guided nerve block simulator is effective for the training of the axillary block technique.

ultrasound-guided nerve blocks are becoming the standard of care in patients requiring regional anesthesia. cost-effective training is needed for the implementation of these techniques in the global anesthesia practice. existing simulators are expensive and not available in low income countries. the investigators aimed to test an inexpensive simulator for the training in this technique.

Eligibility criteria:
inclusion criteria: * anesthesia residents exclusion criteria: * previous training in regional anesthesia techniques
bile duct drainage after ercp failure: eus-bd vs ptbd

Conditions: Pancreatic Cancer; Cholangiocarcinoma; Biliary Obstruction

Summary: the vast majority of patients with distal biliary, pancreatic head or uncinate process cancer have jaundice caused by distal malignant obstruction (dmo) of the common bile duct. biliary drainage by endoscopic retrograde cholangiopancreatography (ercp) with trans-papillary stent placement is the treatment of choice. ercp has a failure rate ranging from 12 - 25 percent. percutaneous transhepatic biliary drainage (ptbd) is the alternative conventional way to drain the biliary tree after ercp failure, which is related with substantial morbidity (62%) and mortality (17%). endoscopic ultrasound (eus)-guided biliary drainage (eus-bd) is a novel promising drainage modality with reported excellent outcomes in terms of clinical success and complications. the implementation of eus-bd besides ercp and ptbd into dutch daily clinical practice raises many questions related to performance, costs, qol, training, implementation and overall oncological treatment success. this structured learning/proctoring program with an additional national registry provides insights into eus-bd and how to implement eus-bd in the dutch standard of care.

the study is designed as a prospective multicenter registry. the data obtained in this study will enable the eus-bd procedure to progress to larger multicenter and preferably randomized control trials.

Eligibility criteria:
inclusion criteria: * 18 years and older * distal malignant cbd obstruction (from ampulla to 1cm distal to the hilum) * indication for biliary drainage after failed ercp-guided biliary drainage exclusion criteria: * previous ptbd and/or eus-bd * inability to provide informed consent * pregnancy * american society of anesthesiology (asa) grade iv-v
evaluating the safety and tolerability of oravescent fentanyl for opioid tolerant patients with noncancer related breakthrough pain

Conditions: Low Back Pain; Migraine; Diabetic Neuropathies; Osteoarthritis

Summary: the purpose of this study is to evaluate the safety and tolerability of oravescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.


Eligibility criteria:
inclusion criteria: * chronic pain diagnosis * opioid tolerant * has on average 1-4 breakthrough pain episodes per day exclusion criteria: * drug abuse history * cardiopulmonary disease * monoamine oxidase inhibitors (maois) * expected to have surgery to relieve the pain

Keywords: pain sudden pain flares noncancer low back pain neuropathic pain osteoarthritis pain migraine chronic headache diabetic peripheral neuropathy
the effect of kinesiotaping in pregnant women

Conditions: KINESIOTAPING

Summary: the aim of this study is to examine the effect of an exercise program combined with kinesio taping (kt) and sham kt on clinical parameters in pregnant women with low back pain. a total of 40 participants were included in the study, 20 in the experimental and 20 in the control groups. visual analog scale (vas), roland morris quality of life questionnaire and pittsburgh sleep quality index were used as data collection tools. the experimental group received kt and an exercise program, while the control group received sham kt and exercise program.

lumbar-sacral spinal pain is a medical and socioeconomic problem affecting approximately 80% of the population. pregnancy predisposes women to this pain. the most well-known cause of low back pain during pregnancy is an increase in lumbar lordosis, a lordotic syndrome that develops rapidly due to the pregnant uterus and maternal weight gain. this lordotic posture and the related change in load distribution, along with lengthening abdominal muscles and shortening lumbar muscles, create a mechanical disadvantage. the aim of this study is to examine the effect of an exercise program combined with kinesio taping (kt) and sham kt on clinical parameters in pregnant women with low back pain. a total of 40 participants were included in the study, 20 in the experimental and 20 in the control groups. visual analog scale (vas), roland morris quality of life questionnaire and pittsburgh sleep quality index were used as data collection tools. the experimental group received kt and an exercise program, while the control group received sham kt and exercise program.

Eligibility criteria:
inclusion criteria: * 20-32-week pregnant women without neurologic deficits * females with mechanical low back pain * vas of at least 3 exclusion criteria: * high-risk pregnant women with twin pregnancy * placenta previa * pre-eclampsia * threatened preterm delivery * orthopedic and rheumatologic diseases * radiculopathy

Keywords: kinesiotaping low back pain pregnancy
the role of occupational therapy for improving medication management for persons with amd, dr and glaucoma

Conditions: Age-Related Macular Degeneration

Summary: the goal of this clinical trial is to learn if education about additional task lighting, enhanced contrast, enlarged print instructions, smart apps and organizational strategies will improve medication management skills. the main questions it aims to answer are: does additional task lighting, enhanced contrast, enlarged print instructions, smart apps and organizational strategies improve medication management skills, reduce errors and improve functional use of remaining vision for this task? participants will: oftentimes, the client is unaware of these strategies which may improve occupational performance during a valued activity. clients with amd, dr or glaucoma who choose to receive the one hour ot service will be provided with 1:1 education regarding the devices and strategies that may improve their ability to perform medication management skills.

many clients with low vision are unaware of ot, or the services ot can provide to assist with low vision needs. clients with amd, dr or glaucoma who choose to receive the one hour ot service will be provided with 1:1 education regarding the devices and strategies that may improve their ability to perform medication management skills. clients will complete the medicog and the revised-self-report assessment of functional visual performance (r-srafvp) assessment tools with the assistance of the ot. these tools will inform the therapist to areas of client needs and allow for focus on intervention to support these challenges. follow up in ot 4 weeks post intervention will allow therapist to reassess the effectiveness of interventions provided via a phone or in-person interview as well as provide the assessments again. second set of data from these assessments will be compared to initial findings obtained.

Eligibility criteria:
inclusion criteria: * clients with amd, dr or glaucoma * clients who choose to participate will allow their deidentified data to be evaluated for outcomes. exclusion criteria: * clients with other age related eye diseases other than amd, dr or glaucoma. * clients who do not wish to participate in this study.
ph+/bcr-abl+ all imatinib and nilotinib rotational study

Conditions: Treatment; Stem Cell Transplantation

Summary: this study is an open-label, multicentric, exploratory, single arm, phase ii study of adults who are either more than 60 years old, or are unfit for intensive chemotherapy and allo sct. the patients are treated with nilotinib, administered orally twice daily, for 6 weeks (course a) followed by imatinib, administered orally twice daily, for other 6 weeks (course b).the courses will be repeated (rotated) for a total of 4 times or until relapse, or until it is in the interest of the patients. prednisone (p) will be administered to all patients for 7-14 days, before tkis, so as to make it possible to wait for the results of cytogenetic and molecular tests, and to evaluate the response to p alone, hence for another 21 days. intrathecal therapy (it) with mtx/arac/dex is mandatory, monthly, in patients without clinical-cytologic evidence of meningeal involvement, while in patients with cns involvement it is performed twice weekly until clearance of leukemic cells, hence once weekly. im will be administered at the dosage of 600 mg daily (300 mg twice daily) and nilotinib at the dosage of 800 mg daily (400 mg twice daily) in all courses. all patients are scheduled to receive at least 4 courses of either drugs, for a total of 4 courses (4 x 6 = 24 weeks). after 4 courses, patients are either allowed to continue the treatment until relapse or progression, if it is in their interest, or to discontinue the treatment and receive other therapies.


Eligibility criteria:
inclusion criteria: * previously untreated ph+ all more than 60 years old or more than 18 years old, but unfit for program of intensive therapy and allogeneic sct

Keywords: untreated ph+ all unfit for intense therapy and allo sct
sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (s-access)

Conditions: Cerebral Infarction

Summary: sarpogrelate (mci-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-ht) levels in platelets via a blockade of 5-ht2 receptors; it has been used in atherosclerotic peripheral arterial disease. s-access was a randomized, double-blinded trial to compare the relative efficacy of sarpogrelate (100mg three times daily) and aspirin (81mg once daily) in 1510 patients with recent cerebral infarction. patients were followed for 0.9 to 3.5 years. the primary endpoint was recurrence of cerebral infarction; relative safety was also assessed.


Eligibility criteria:
inclusion criteria: * cerebral infarction except cardiac source of embolism * onset ≧ 1 week to ≦ 6 months before randomization * neurological signs persisting ≧ 1 day from onset * computed tomography (ct) or magnetic resonance imaging (mri) detection of responsible site * age ≧ 20 years * systolic pressure ≦ 180 mmhg; diastolic pressure ≦ 110 mmhg exclusion criteria: * functional outcome at randomization: modified rankin scale = 4, 5 * previous or planned vascular surgery for cerebral infarction * history of intracranial hemorrhage * history of systemic bleeding, or other history of bleeding diathesis or coagulopathy * severe complications (renal or hepatic insufficiency, heart failure, hemopathy, etc.) * pregnant or possibly pregnant women, or nursing mothers * history of sarpogrelate and aspirin sensitivity * treating malignant tumor or treated within 5 years * current peptic ulceration